Abstract: 
Over the past two decades, fast disintegrating tablets have gained global attention as a fast-rising alternative to conventional tablets by providing solutions to the limitations and disadvantages of earlier dosage forms administered orally. Valsartan sodium was formulated into tablets using the direct compression method. Different formulation batches were developed. Batches A1 to A3 contained fixed API, sodium starch glycolate, cellactose and mannitol in varying proportion; B1 to B3 contained fixed API, croscarmellose sodium, cellactose, and PEG 4000; C1 to C3, contained fixed API, SSG, cellactose, mannitol and PEG 4000 (50:50); D1 to D3 contained fixed API, CCS, cellactose, MN and PEG 4000 (50:50). The pre formulation characteristics of all powder mixtures showed good flow and compressibility properties. Batches A1 – A3 tablets containing mannitol were harder than B1 – B3 containing PEG 4000. From the results,  C1 and D1 contained both MN and PEG 4000 in different proportion, PEG was responsible for lower tablet hardness, while both excipients played positive role in lowering disintegration time, C1 with average hardness and lower DT (47 .53 N, 6.44 s) will be adequate for FDT design for mouth disintegration on one hand, and A2 or A3 with hardness and DT:107.8 N, 7.21 s and 91.54 N, 6.80 s respectively could be best applied for the FDT intended to withstand rough handling transportation for commerce. The FTIR analysis of batches A to D showed no changes in the API peaks when compared with that of valsartan drug.

Keywords: Valsartan, Mouth Disintegrating, Fast Disintegrating, Rapid Disintegrating, Orodispersible.